Roots Analysis: AAV Vector Manufacturing Market Expands
Roots Analysis has published a study on AAV vector manufacturing, highlighting significant market growth potential driven by the increasing demand for gene therapies and personalized medicines.
Market research firm Roots Analysis has released a comprehensive study detailing the landscape of Adeno-Associated Virus (AAV) vector manufacturing and emerging trends. AAV vectors are recognized as a fundamental delivery platform in gene therapies, essential for their ability to transport therapeutic genetic material to target cells.
The report anticipates substantial growth in the AAV vector market over the next decade. This expansion is largely attributed to the rising demand for gene therapies and personalized medicine. The capacity to produce high-quality AAV vectors at scale, with improved yields and cost-efficiency, is identified as a critical factor for advancing these treatments towards commercialization.
Key players identified in the AAV vector manufacturing sector include Catalent Biologics, Cytiva, Lonza, Sanofi, and Thermo Fisher Scientific. These companies are noted for their contributions to process development, manufacturing capacity, and specialized technologies supporting gene therapy production.
Advancements in process development, regulatory frameworks, and manufacturing capacity are collectively shaping a more efficient future for AAV-based gene therapies. The study underscores the growing importance of this sector in delivering innovative medical treatments.